Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
- Status
- RECRUITING
- Phase
- PHASE1
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab in High-risk Thyroid Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1